Identification

Name
Ranitidine
Accession Number
DB00863  (APRD00254)
Type
Small Molecule
Groups
Approved
Description

A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. [PubChem]

Structure
Thumb
Synonyms
  • RAN
  • Ranitidina
  • Ranitidinum
Product Ingredients
IngredientUNIICASInChI Key
Ranitidine bismuth citrate7AJ51I17KG128345-62-0XAUTYMZTJWXZHZ-UHFFFAOYSA-K
Ranitidine HydrochlorideBK76465IHM66357-59-3GGWBHVILAJZWKJ-KJEVSKRMSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acid ReducerTablet150 mgOralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
Act RanitidineTablet300 mgOralTeva2004-02-19Not applicableCanada
Act RanitidineTablet150 mgOralTeva2004-04-19Not applicableCanada
Bci RanitidineTablet150 mgOralBaker Cummins IncNot applicableNot applicableCanada
Bci RanitidineTablet300 mgOralBaker Cummins IncNot applicableNot applicableCanada
Dom-ranitidineTablet150 mgOralDominion Pharmacal2001-03-22Not applicableCanada
Dom-ranitidineTablet300 mgOralDominion Pharmacal2001-03-22Not applicableCanada
Jamp-ranitidineTablet150 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-ranitidineTablet300 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
Mar-ranitidineTablet150 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-ranitidineSolution75 mgOralApotex Corporation2006-07-14Not applicableCanada
Apo-ranitidine Tablet 150mgTablet150 mgOralApotex Corporation1987-12-31Not applicableCanada
Apo-ranitidine Tablet 300mgTablet300 mgOralApotex Corporation1987-12-31Not applicableCanada
Good Sense Acid ReducerTablet75 mg/1Oralbryant ranch prepack2009-05-21Not applicableUs
RanitidineTablet, film coated150 mg/1OralRemedy Repack2017-10-20Not applicableUs
RanitidineTablet300 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2009-12-16Not applicableUs
RanitidineTablet300 mg/1OralAphena Pharma Solutions Tennessee, Inc.2014-08-18Not applicableUs
RanitidineTablet, film coated150 mg/1OralNucare Pharmaceuticals, Inc.2008-11-19Not applicableUs
RanitidineTablet150 mg/1OralRemedy Repack2015-07-222017-02-18Us
RanitidineTablet150 mg/1OralRemedy Repack2017-02-15Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
7 Select Acid ReducerTablet, film coated150 mg/1Oral7 Eleven2014-04-22Not applicableUs
Acid ReducerTablet, coated150 mg/1OralCVS Health2010-05-01Not applicableUs
Acid ReducerTablet150 mg/1OralPremier Value2012-03-30Not applicableUs
Acid ReducerTablet150 mg/1OralOhm Laboratories, Inc.2011-06-28Not applicableUs
Acid ReducerTablet75 mgOralVita Health Products Inc2006-03-312009-08-06Canada
Acid ReducerTablet, film coated75 mg/1OralSafeway2013-12-13Not applicableUs
Acid ReducerTablet, film coated150 mg/1OralShopko Stores Operating2013-06-05Not applicableUs
Acid ReducerTablet75 mgOralWestcan Pharmaceuticals Ltd.Not applicableNot applicableCanada
Acid ReducerTablet150 mgOralApotex Corporation2014-03-20Not applicableCanada
Acid ReducerTablet150 mg/1OralWalmart Stores2013-09-09Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DeprizineKitCalifornia Pharmaceuticals, Llc2016-01-01Not applicableUs
RanitidineTablet, film coated300 mg/1OralDirectrx2014-01-01Not applicableUs
Ranitidine 150Tablet, coated150 mg/1OralMarc Glassman, Inc.2010-01-05Not applicableUs
Ranitidine 150Tablet, coated150 mg/1OralAllegiant Health2010-01-05Not applicableUs
Ranitidine HydrochlorideTablet, film coated300 mg/1OralDirectrx2017-11-06Not applicableUs
International/Other Brands
Alquen / Coralen / Gastrolav / Gastrosedol / Kuracid / Nu-Ranit / Pep-Rani / Ptinolin / Raniberl / Ranibloc / Ranicux / Ranidil / Ranidin / Ranidine / Ranidura / Ranifur / Ranigast / Raniplex / Ranisan / Ranitab / Ranitic / Ranitidin / Ranitin / Ranitine / Ranobel / Rantacid / Ranuber / Renatac / Sostril / Tanidina / Toriol / Ulcodin / Zandid / Zantic
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
GabitidineRanitidine Hydrochloride + CholineKitPhysician Therapeutics Llc2011-07-072016-10-13Us
SentradineRanitidine Hydrochloride + CholineKitPhysician Therapeutics Llc2011-07-072016-10-13Us
Categories
UNII
884KT10YB7
CAS number
66357-35-5
Weight
Average: 314.404
Monoisotopic: 314.14126128
Chemical Formula
C13H22N4O3S
InChI Key
VMXUWOKSQNHOCA-UKTHLTGXSA-N
InChI
InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+
IUPAC Name
dimethyl[(5-{[(2-{[(E)-1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}furan-2-yl)methyl]amine
SMILES
CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O

Pharmacology

Indication

Used in the treatment of peptic ulcer disease (PUD), dyspepsia, stress ulcer prophylaxis, and gastroesophageal reflux disease (GERD).

Structured Indications
Pharmacodynamics

Ranitidine is a histamine H2-receptor antagonist similar to cimetidine and famotidine. An H2-receptor antagonist, often shortened to H2 antagonist, is a drug used to block the action of histamine on parietal cells in the stomach, decreasing acid production by these cells. These drugs are used in the treatment of dyspepsia, however their use has waned since the advent of the more effective proton pump inhibitors. Like the H1-antihistamines, the H2 antagonists are inverse agonists rather than true receptor antagonists.

Mechanism of action

The H2 antagonists are competitive inhibitors of histamine at the parietal cell H2 receptor. They suppress the normal secretion of acid by parietal cells and the meal-stimulated secretion of acid. They accomplish this by two mechanisms: histamine released by ECL cells in the stomach is blocked from binding on parietal cell H2 receptors which stimulate acid secretion, and other substances that promote acid secretion (such as gastrin and acetylcholine) have a reduced effect on parietal cells when the H2 receptors are blocked.

TargetActionsOrganism
AHistamine H2 receptor
antagonist
Human
UAcetylcholinesteraseNot AvailableHuman
UCholinesteraseNot AvailableHuman
Absorption

Approximately 50% bioavailability orally.

Volume of distribution
  • 1.4 L/kg
  • 1.76 L/kg [clinically significant renal function impairment (creatinine clearance 25 to 35 mL/min)]
Protein binding

15%

Metabolism

Hepatic. Ranitidine is metabolized to the N-oxide, S-oxide, and N-desmethyl metabolites, accounting for approximately 4%, 1%, and 1% of the dose, respectively.

Route of elimination

The principal route of excretion is the urine (active tubular excretion, renal clearance 410mL/min), with approximately 30% of the orally administered dose collected in the urine as unchanged drug in 24 hours.

Half life

2.8-3.1 hours

Clearance
  • 29 mL/min [clinically significant renal function impairment]
  • 3 mL/min/Kg [neonatal patients]
Toxicity

LD50=77mg/kg (orally in mice). Symptoms of overdose include muscular tremors, vomiting, and rapid respiration.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Ranitidine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Ranitidine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Ranitidine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Ranitidine.Experimental, Illicit
AbirateroneThe serum concentration of Ranitidine can be increased when it is combined with Abiraterone.Approved
AcetohexamideThe serum concentration of Acetohexamide can be increased when it is combined with Ranitidine.Investigational, Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Ranitidine.Approved
AmiodaroneThe metabolism of Ranitidine can be decreased when combined with Amiodarone.Approved, Investigational
AmphetamineAmphetamine may decrease the sedative activities of Ranitidine.Approved, Illicit
ArmodafinilThe metabolism of Ranitidine can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe metabolism of Ranitidine can be decreased when combined with Artemether.Approved
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Ranitidine.Approved, Investigational
AtomoxetineThe metabolism of Ranitidine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Ranitidine is combined with Atorvastatin.Approved
AzithromycinThe metabolism of Ranitidine can be decreased when combined with Azithromycin.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Ranitidine.Approved, Illicit
Benzylpenicilloyl PolylysineRanitidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Ranitidine.Approved
BetaxololThe metabolism of Ranitidine can be decreased when combined with Betaxolol.Approved
BortezomibThe metabolism of Ranitidine can be decreased when combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Ranitidine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ranitidine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ranitidine.Approved, Investigational
BupropionThe metabolism of Ranitidine can be decreased when combined with Bupropion.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ranitidine.Approved
CaffeineThe metabolism of Ranitidine can be decreased when combined with Caffeine.Approved
CarbamazepineThe metabolism of Ranitidine can be increased when combined with Carbamazepine.Approved, Investigational
CarbutamideThe serum concentration of Carbutamide can be increased when it is combined with Ranitidine.Experimental
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Ranitidine.Approved
CefpodoximeRanitidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CefuroximeRanitidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CelecoxibThe metabolism of Ranitidine can be decreased when combined with Celecoxib.Approved, Investigational
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ranitidine.Withdrawn
ChloramphenicolThe metabolism of Ranitidine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe metabolism of Ranitidine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Ranitidine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Ranitidine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Chlorpropamide can be increased when it is combined with Ranitidine.Approved
CholecalciferolThe metabolism of Ranitidine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Ranitidine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Ranitidine can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Ranitidine can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Ranitidine can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Ranitidine can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Ranitidine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe metabolism of Ranitidine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Ranitidine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Ranitidine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Ranitidine can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Ranitidine.Approved
Cyproterone acetateThe serum concentration of Ranitidine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Ranitidine.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ranitidine.Approved
DabrafenibThe serum concentration of Ranitidine can be decreased when it is combined with Dabrafenib.Approved
DarifenacinThe metabolism of Ranitidine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Ranitidine can be increased when it is combined with Darunavir.Approved
DasatinibRanitidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeferasiroxThe serum concentration of Ranitidine can be increased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Ranitidine.Approved
DesipramineThe metabolism of Ranitidine can be decreased when combined with Desipramine.Approved
DexmethylphenidateRanitidine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Ranitidine.Approved, Illicit
DiethylpropionDiethylpropion may decrease the sedative activities of Ranitidine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ranitidine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ranitidine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Ranitidine.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ranitidine.Approved
DiphenhydramineThe metabolism of Ranitidine can be decreased when combined with Diphenhydramine.Approved
DosulepinThe metabolism of Ranitidine can be decreased when combined with Dosulepin.Approved
DoxofyllineThe serum concentration of Doxofylline can be increased when it is combined with Ranitidine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ranitidine.Approved, Investigational
DronedaroneThe metabolism of Ranitidine can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Ranitidine can be decreased when combined with Duloxetine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Ranitidine.Approved
EfavirenzThe metabolism of Ranitidine can be decreased when combined with Efavirenz.Approved, Investigational
EliglustatThe metabolism of Ranitidine can be decreased when combined with Eliglustat.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ranitidine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Ranitidine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Ranitidine.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Ranitidine can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Ranitidine can be decreased when combined with Esomeprazole.Approved, Investigational
EtravirineThe metabolism of Ranitidine can be decreased when combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Ranitidine.Approved
Ferric CarboxymaltoseRanitidine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateRanitidine can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Ferric pyrophosphateRanitidine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ranitidine.Approved
FluconazoleThe metabolism of Ranitidine can be decreased when combined with Fluconazole.Approved
FluoxetineThe metabolism of Ranitidine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Ranitidine.Approved
FluvoxamineThe metabolism of Ranitidine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Ranitidine.Approved
FosphenytoinThe metabolism of Ranitidine can be increased when combined with Fosphenytoin.Approved
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Ranitidine.Approved, Investigational
GemfibrozilThe metabolism of Ranitidine can be decreased when combined with Gemfibrozil.Approved
GepefrineGepefrine may decrease the sedative activities of Ranitidine.Experimental
GlibornurideThe serum concentration of Glibornuride can be increased when it is combined with Ranitidine.Investigational, Withdrawn
GliclazideThe serum concentration of Gliclazide can be increased when it is combined with Ranitidine.Approved
GlimepirideThe serum concentration of Glimepiride can be increased when it is combined with Ranitidine.Approved
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Ranitidine.Approved
GliquidoneThe serum concentration of Gliquidone can be increased when it is combined with Ranitidine.Approved, Investigational
GlisoxepideThe serum concentration of Glisoxepide can be increased when it is combined with Ranitidine.Approved, Investigational
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Ranitidine.Approved
HaloperidolThe metabolism of Ranitidine can be decreased when combined with Haloperidol.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ranitidine.Approved, Investigational
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Ranitidine.Approved
ImipramineThe metabolism of Ranitidine can be decreased when combined with Imipramine.Approved
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Ranitidine.Approved
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Ranitidine.Approved
IronRanitidine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranRanitidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateRanitidine can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsoniazidThe metabolism of Ranitidine can be decreased when combined with Isoniazid.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Ranitidine.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Ranitidine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Ranitidine.Approved
LidocaineThe metabolism of Ranitidine can be decreased when combined with Lidocaine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Ranitidine.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Ranitidine.Approved, Investigational
LobeglitazoneThe metabolism of Ranitidine can be decreased when combined with Lobeglitazone.Approved, Investigational
LopinavirThe metabolism of Ranitidine can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Ranitidine can be decreased when combined with Lorcaserin.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Ranitidine.Approved, Investigational
LuliconazoleThe serum concentration of Ranitidine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Ranitidine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Ranitidine can be decreased when combined with Lumefantrine.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Ranitidine.Illicit, Investigational, Withdrawn
ManidipineThe metabolism of Ranitidine can be decreased when combined with Manidipine.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Ranitidine.Investigational
MephentermineMephentermine may decrease the sedative activities of Ranitidine.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Ranitidine.Approved
MetahexamideThe serum concentration of Metahexamide can be increased when it is combined with Ranitidine.Experimental
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Ranitidine.Experimental
MethadoneThe metabolism of Ranitidine can be decreased when combined with Methadone.Approved
MethamphetamineMethamphetamine may decrease the sedative activities of Ranitidine.Approved, Illicit
MethotrimeprazineThe metabolism of Ranitidine can be decreased when combined with Methotrimeprazine.Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Ranitidine.Experimental
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ranitidine.Approved
MethylphenidateRanitidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Ranitidine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Ranitidine.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Ranitidine.Experimental
MexiletineThe metabolism of Ranitidine can be decreased when combined with Mexiletine.Approved
MidomafetamineMidomafetamine may decrease the sedative activities of Ranitidine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Ranitidine can be decreased when combined with Midostaurin.Approved
MirabegronThe metabolism of Ranitidine can be decreased when combined with Mirabegron.Approved
MMDAMMDA may decrease the sedative activities of Ranitidine.Experimental, Illicit
MoclobemideThe metabolism of Ranitidine can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Ranitidine can be decreased when combined with Modafinil.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ranitidine.Approved
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Ranitidine.Approved
NevirapineThe metabolism of Ranitidine can be decreased when combined with Nevirapine.Approved
NicardipineThe metabolism of Ranitidine can be decreased when combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Ranitidine.Approved, Investigational
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Ranitidine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Ranitidine.Approved
OmeprazoleThe metabolism of Ranitidine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Ranitidine can be decreased when it is combined with Osimertinib.Approved
PanobinostatThe serum concentration of Ranitidine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Ranitidine can be decreased when combined with Pantoprazole.Approved
ParoxetineThe metabolism of Ranitidine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Ranitidine.Approved
Peginterferon alfa-2bThe serum concentration of Ranitidine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Ranitidine.Approved, Investigational, Vet Approved, Withdrawn
PhenterminePhentermine may decrease the sedative activities of Ranitidine.Approved, Illicit
PhenytoinThe metabolism of Ranitidine can be increased when combined with Phenytoin.Approved, Vet Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ranitidine.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Ranitidine.Approved, Investigational, Vet Approved
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Ranitidine resulting in a loss in efficacy.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Ranitidine.Approved
ProcainamideThe serum concentration of Procainamide can be increased when it is combined with Ranitidine.Approved
PromazineThe metabolism of Ranitidine can be decreased when combined with Promazine.Approved, Vet Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Ranitidine.Approved
PseudoephedrinePseudoephedrine may decrease the sedative activities of Ranitidine.Approved
QuinidineThe metabolism of Ranitidine can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Ranitidine can be decreased when combined with Quinine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Ranitidine.Approved, Investigational
RifampicinThe metabolism of Ranitidine can be increased when combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Ranitidine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Ranitidine.Approved
RisedronateThe serum concentration of Risedronate can be increased when it is combined with Ranitidine.Approved, Investigational
RitobegronRitobegron may decrease the sedative activities of Ranitidine.Investigational
RitonavirThe metabolism of Ranitidine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Ranitidine can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Ranitidine can be decreased when combined with Ropinirole.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Ranitidine.Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Ranitidine.Approved, Investigational
SertralineThe metabolism of Ranitidine can be decreased when combined with Sertraline.Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Ranitidine.Approved
SimeprevirThe metabolism of Ranitidine can be decreased when combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Ranitidine.Approved
StiripentolThe metabolism of Ranitidine can be decreased when combined with Stiripentol.Approved
Tenofovir disoproxilThe metabolism of Ranitidine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Ranitidine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Ranitidine.Experimental
TeriflunomideThe serum concentration of Ranitidine can be decreased when it is combined with Teriflunomide.Approved
TheophyllineThe metabolism of Ranitidine can be decreased when combined with Theophylline.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Ranitidine.Approved, Withdrawn
TiclopidineThe metabolism of Ranitidine can be decreased when combined with Ticlopidine.Approved
TipranavirThe metabolism of Ranitidine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Ranitidine.Approved
TolazamideThe serum concentration of Tolazamide can be increased when it is combined with Ranitidine.Approved
TolbutamideThe serum concentration of Tolbutamide can be increased when it is combined with Ranitidine.Approved
TopiramateThe metabolism of Ranitidine can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Ranitidine.Approved, Investigational
TranylcypromineThe metabolism of Ranitidine can be decreased when combined with Tranylcypromine.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Ranitidine.Approved, Experimental
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Ranitidine.Approved, Investigational
VemurafenibThe serum concentration of Ranitidine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Ranitidine can be decreased when combined with Venlafaxine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Ranitidine.Approved, Investigational
VoriconazoleThe metabolism of Ranitidine can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Ranitidine.Approved
ZiprasidoneThe metabolism of Ranitidine can be decreased when combined with Ziprasidone.Approved
ZucapsaicinThe metabolism of Ranitidine can be decreased when combined with Zucapsaicin.Approved
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
  • Take without regard to meals.

References

Synthesis Reference

John W. Clitherow, "Intermediates in the preparation of ranitidine." U.S. Patent US4413135, issued November, 1981.

US4413135
General References
Not Available
External Links
Human Metabolome Database
HMDB01930
KEGG Drug
D00422
PubChem Compound
3001055
PubChem Substance
46505543
ChemSpider
2272523
BindingDB
50103506
ChEBI
8776
ChEMBL
CHEMBL512
Therapeutic Targets Database
DAP000340
PharmGKB
PA451224
IUPHAR
1234
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ranitidine
ATC Codes
A02BA07 — Ranitidine bismuth citrateA02BA02 — Ranitidine
AHFS Codes
  • 56:28.12 — Histamine H2-antagonists
FDA label
Download (247 KB)
MSDS
Download (73.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentPharmacokinetics / Voriconazole1
1CompletedNot AvailableAutonomic Failure / Idiopathic orthostatic hypotension1
1CompletedBasic Science(t1/2,λz) / Cmax / Pharmacokinetics / Plasma [AUC(0-672)] / Plasma [AUC(0-t)] / Plasma AUC / Tmax1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic SciencePharmacokinetics1
1CompletedBasic ScienceReflux Esophagitis (RE)1
1CompletedTreatmentHealthy Volunteers5
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1RecruitingBasic ScienceChronic Obstructive Pulmonary Disease (COPD) / Heart Failure, Unspecified / Hypertensive / Pulmonary Arterial Hypertension (PAH)1
2CompletedDiagnosticGastroesophageal Reflux Disease / Reflux, Gastroesophageal1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentRenal Cell Adenocarcinoma1
2Not Yet RecruitingPreventionPost Anaesthetic Shivering1
2RecruitingTreatmentPlasma Cell Myeloma1
2RecruitingTreatmentPostpartum Hemorrhage1
2RecruitingTreatmentT-cell Type Acute Leukemia-Precursor T-lymphoblastic Lymphoma/Leukaemia1
2TerminatedTreatmentHyper IgE Syndromes / Hyper-IgE Recurrent Infection Syndrome / Immune Deficiencies1
2, 3CompletedTreatmentHelicobacter Pylori [H. Pylori] as the Cause of Diseases1
3CompletedTreatmentGastric Ulcer (GU)1
3CompletedTreatmentGastroesophageal Reflux Disease (GERD)2
3CompletedTreatmentNSAID Associated Gastric Ulcers2
3CompletedTreatmentReflux, Gastroesophageal1
3TerminatedHealth Services ResearchCoughing1
3TerminatedTreatmentEsophageal Metaplasia1
4CompletedTreatmentAntimicrobial Drug Susceptibility Pattern / Etiological Organisms / Stress Ulcer Prophylaxis / Ventilator-associated Bacterial Pneumonia1
4CompletedTreatmentCoronary Artery Disease / VA Drug Interactions [VA Drug Interaction]1
4CompletedTreatmentCritically Ill Patients / Indication for Stress Ulcer Prophylaxis1
4CompletedTreatmentIndigestion2
4CompletedTreatmentProstate Cancer1
4CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
4Enrolling by InvitationTreatmentAnesthesia Complication / Hemodynamics Instability / Ileus paralytic / Nausea / Postoperative pain / Vomiting1
4RecruitingTreatmentWet Macular Degeneration1
4WithdrawnPreventionPeptic Ulcers1
4WithdrawnTreatmentEustachian Tube Dysfunction / Laryngopharyngeal Reflux1
Not AvailableCompletedNot AvailableCommunity Acquired Pneumonia (CAP) / Gastroesophageal Reflux Disease (GERD)1
Not AvailableCompletedNot AvailableStrokes1
Not AvailableCompletedSupportive CareAntiplatelet Effect1
Not AvailableCompletedTreatmentGastrointestinal Diseases / Indigestion1
Not AvailableUnknown StatusPreventionPoisoning1

Pharmacoeconomics

Manufacturers
  • Dr reddys laboratories ltd
  • Genpharm inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Glaxosmithkline
  • Bedford laboratories div ben venue laboratories inc
  • Ben venue laboratories inc
  • Alpharma us pharmaceuticals division
  • Amneal pharmaceuticals
  • Apotex inc
  • Aurobindo pharma usa inc
  • Cypress pharmaceutical inc
  • Pharmaceutical assoc inc div beach products
  • Ranbaxy laboratories ltd
  • Vintage pharmaceuticals inc
  • Wockhardt ltd
  • Boehringer ingelheim pharmaceuticals inc
  • Amneal pharmaceuticals ny llc
  • Boehringer ingelheim corp
  • Contract pharmacal corp
  • Dr reddys laboratories inc
  • Glenmark generics inc usa
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • L perrigo co
  • Ranbaxy pharmaceuticals inc
  • Torpharm inc
  • Watson laboratories inc
  • Wockhardt americas inc
  • Boehringer ingelheim
Packagers
Dosage forms
FormRouteStrength
TabletOral75.0 mg
TabletOral150 mg/1
Kit
Kit
Tablet, film coatedOral150 mg/1
Tablet, coatedOral150 mg/1
TabletOral400 mg
SolutionOral15 mg/mL
SolutionOral150 mg/mL
SyrupOral15 mg/mL
SyrupTopical15 mg/mL
TabletOral300 mg/1
Tablet, coatedOral75 mg/1
Tablet, film coatedOral300 mg/1
Tablet, film coatedOral75 mg/1
CapsuleOral150 mg/1
CapsuleOral300 mg/1
InjectionIntramuscular; Intravenous25 mg/mL
SolutionOral150 mg/10mL
SolutionOral75 mg/5mL
TabletOral75 mg
TabletOral150 mg
TabletOral300 mg
SolutionIntramuscular; Intravenous25 mg
SolutionOral75 mg
TabletOral75 mg/1
Injection, solutionIntramuscular; Intravenous25 mg/mL
LiquidIntramuscular; Intravenous25 mg
SolutionIntramuscular; Intravenous50 mg
SolutionOral15 mg
CapsuleOral150 mg
CapsuleOral300 mg
Prices
Unit descriptionCostUnit
Zantac 300 mg tablet7.96USD tablet
Ranitidine hcl powder5.2USD g
Zantac EFFERdose 25 mg Effervescent Tabs4.18USD tab
Zantac 25 efferdose tablet4.02USD tablet
Zantac 150 mg tablet3.11USD tablet
Ranitidine HCl 300 mg capsule2.85USD capsule
Ranitidine HCl 300 mg tablet2.79USD tablet
Ranitidine 300 mg tablet2.69USD tablet
Ranitidine hcl 25 mg/ml vial2.0USD ml
Zantac 25 mg/ml vial2.0USD ml
Ranitidine HCl 150 mg capsule1.58USD capsule
Zantac 25 mg/ml1.58USD ml
Ranitidine HCl 150 mg tablet1.54USD tablet
Ranitidine 150 mg tablet1.48USD tablet
Ranitidine 25 mg/ml1.26USD ml
Ranitidine HCl 15 mg/ml Syrup1.0USD ml
Ratio-Ranitidine 300 mg Tablet0.82USD tablet
Apo-Ranitidine 300 mg Tablet0.82USD tablet
Co Ranitidine 300 mg Tablet0.82USD tablet
Mylan-Ranitidine 300 mg Tablet0.82USD tablet
Nu-Ranit 300 mg Tablet0.82USD tablet
Pms-Ranitidine 300 mg Tablet0.82USD tablet
Ran-Ranitidine 300 mg Tablet0.82USD tablet
Zantac 15 mg/ml Syrup0.81USD ml
Zantac 75 tablet0.49USD tablet
Apo-Ranitidine 150 mg Tablet0.42USD tablet
Co Ranitidine 150 mg Tablet0.42USD tablet
Mylan-Ranitidine 150 mg Tablet0.42USD tablet
Nu-Ranit 150 mg Tablet0.42USD tablet
Pms-Ranitidine 150 mg Tablet0.42USD tablet
Ran-Ranitidine 150 mg Tablet0.42USD tablet
Ratio-Ranitidine 150 mg Tablet0.42USD tablet
Novo-Ranidine 300 mg Tablet0.38USD tablet
Phl-Ranitidine 300 mg Tablet0.38USD tablet
Sandoz Ranitidine 300 mg Tablet0.38USD tablet
Zantac 300 mg Tablet0.38USD tablet
Zantac 75 mg tablet0.28USD tablet
Wal-zan 75 mg tablet0.27USD tablet
Zantac 15 mg/ml Solution0.23USD ml
Ranitidine hcl 75 mg tablet0.22USD tablet
Sm acid reducer 75 mg tablet0.22USD tablet
Acid reducer 150 mg tablet0.2USD tablet
Wal-zan 75 tablet0.2USD tablet
Novo-Ranidine 150 mg Tablet0.19USD tablet
Phl-Ranitidine 150 mg Tablet0.19USD tablet
Sandoz Ranitidine 150 mg Tablet0.19USD tablet
Zantac 150 mg Tablet0.19USD tablet
CVS Pharmacy ranitidine 75 mg tablet0.15USD tablet
Apo-Ranitidine 15 mg/ml Solution0.12USD ml
Novo-Ranidine 15 mg/ml Solution0.12USD ml
Acid reducer 75 mg tablet0.11USD tablet
CVS Pharmacy acid reducer 75 mg tablet0.11USD tablet
Qc ranitidine 75 mg tablet0.07USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5098715No1993-12-202010-12-20Us
US5102665No1992-12-232009-12-23Us
CA1332610No1994-10-182011-10-18Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)69-70 °CPhysProp
water solubility24.7 mg/mLNot Available
logP0.27SANGSTER (1993)
Caco2 permeability-6.31ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0795 mg/mLALOGPS
logP0.79ALOGPS
logP0.98ChemAxon
logS-3.6ALOGPS
pKa (Strongest Basic)8.08ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area86.26 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity95.15 m3·mol-1ChemAxon
Polarizability33.58 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9936
Blood Brain Barrier-0.8783
Caco-2 permeable-0.5838
P-glycoprotein substrateSubstrate0.8527
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8893
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.7702
CYP450 2D6 substrateSubstrate0.7414
CYP450 3A4 substrateNon-substrate0.5565
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7819
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8077
BiodegradationNot ready biodegradable0.9249
Rat acute toxicity2.0903 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8628
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-01ot-7906000000-d0c73cd55f0c88b5292c
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-004j-2900000000-72810aa2bdb337010c71
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-0f92-3900000000-4984706aec6a10a3a701
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, NegativeLC-MS/MSsplash10-03di-0009000000-3a9ffadb8ced05c4f2f1
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, NegativeLC-MS/MSsplash10-006x-0900000000-26410712c1d9fca3970f
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, NegativeLC-MS/MSsplash10-02ml-0900000000-b8d8d8a38eb5ff79811d
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, NegativeLC-MS/MSsplash10-03di-2900000000-417be0cb4c8a324c3ae4
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, NegativeLC-MS/MSsplash10-03di-5900000000-ca80edf051507a622e91
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, PositiveLC-MS/MSsplash10-014i-0009000000-e8f56e6282043759674e
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, PositiveLC-MS/MSsplash10-00vi-0933000000-aaee0f5a149286ba8834
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, PositiveLC-MS/MSsplash10-0059-1900000000-52e4e1bcfef85a6bafea
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, PositiveLC-MS/MSsplash10-0faj-2900000000-e412e77b79750d8bb513
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, PositiveLC-MS/MSsplash10-0uea-4900000000-76d786153c89ecf65f8c
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-00fr-0930000000-01f54848489d6a7b4da4
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-00di-0970000000-49b8e0b710b97f5d5da6
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-00kf-0900000000-cf634d229fba340e6e3b
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-001i-0900000000-09008c251fc8dd33b8bf
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-00e9-4900000000-350ded3a1f334f8103b1
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-052f-0900000000-14196f34248aa3cac7fc
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-0f79-0900000000-0a386c1d346e41534469
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-0udi-0900000000-4296a8171c03e3b2b689
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0900000000-03ff389cfe57bfe1fd9c
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0609000000-b84b01672e464bc22fd3
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00dl-0900000000-89c78d833473150dbb81
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-02ml-0900000000-5841cf0c06dbaf954888
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0900000000-16045980b681df0f594e
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0900000000-d5953e08a3cb69d2aa2b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0900000000-a96b0d1efb86be171a6c
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0509000000-9a6f4001c5a99813717f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00dl-0900000000-388913e38d155f159d8d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-02ml-0900000000-ee40ae04c260a3e09d17
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-1900000000-abb56ffad9b8b3657fcd
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0900000000-fc2323b7a02a32a4979b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0900000000-417353715450c67cfd73
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03di-0009000000-3a9ffadb8ced05c4f2f1
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-006x-0900000000-26410712c1d9fca3970f
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-02ml-0900000000-b8d8d8a38eb5ff79811d
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03di-2900000000-417be0cb4c8a324c3ae4
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03di-5900000000-ca80edf051507a622e91
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0920000000-fc5b810da0b99c7a47cc
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0059-0900000000-563bf123943826a4ee15
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0059-0900000000-a889fa5e489d1d1c27fc
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004j-0900000000-fd0ea2e984b4ce58b9df
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0009000000-38d3c73e4bffe2808538
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0970000000-8fe41e639371ccd5e039
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0009000000-e04b1b88fd5e019229ed
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-1910000000-c598e7dc2ece622bf853
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-1900000000-cd58b43d9168d2d35586
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ugj-2900000000-dfaf3c18a40f92e31b5c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ugj-3900000000-6bf7695693403dfcd90e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f8a-6900000000-6641dd270863ff1455a6
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0009000000-4e5b09bcb0bf176315fd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-1910000000-7843ceb16946d25ec84e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-1900000000-e766825d33d37bb6a6ca
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ugj-2900000000-7bdea76f53e7741a40ea
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ugj-3900000000-19db1770011ff7821179
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f8a-5900000000-832e92905bd741949ba1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0970000000-d42ebac033e2666b1a5a
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-0009000000-e8f56e6282043759674e
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00vi-0933000000-6c2174f482eeb1972875
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0059-1900000000-80d184a4a9e276c6febc
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0faj-2900000000-e412e77b79750d8bb513
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0uea-4900000000-8328552b5ee619f35b40
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-00fr-0930000000-3b023ec7d141989d3665
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0fba-1900000000-2ae676ccc8236775fb31
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ugj-3900000000-839171139828c12c8e0b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0970000000-272c202bff43d84dc736
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0960000000-05f9a8cbabf7dc30eb5d
MS/MS Spectrum - , positiveLC-MS/MSsplash10-01di-0934000000-7c7227a3ac57df988aee
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Aralkylamines
Alternative Parents
Heteroaromatic compounds / Furans / Trialkylamines / C-nitro compounds / Sulfenyl compounds / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Organic oxoazanium compounds / Dialkylthioethers / Dialkylamines
show 5 more
Substituents
Aralkylamine / Furan / Heteroaromatic compound / C-nitro compound / Tertiary amine / Tertiary aliphatic amine / Organic nitro compound / Secondary aliphatic amine / Organic oxoazanium / Secondary amine
show 16 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
C-nitro compound, tertiary amino compound, furans (CHEBI:8776)

Targets

Details
1. Histamine H2 receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and diff...
Gene Name
HRH2
Uniprot ID
P25021
Uniprot Name
Histamine H2 receptor
Molecular Weight
40097.65 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Pattichis K, Louca LL: Histamine, histamine H2-receptor antagonists, gastric acid secretion and ulcers: an overview. Drug Metabol Drug Interact. 1995;12(1):1-36. [PubMed:7554999]
Details
2. Acetylcholinesterase
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine hydrolase activity
Specific Function
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name
ACHE
Uniprot ID
P22303
Uniprot Name
Acetylcholinesterase
Molecular Weight
67795.525 Da
References
  1. Petroianu GA, Arafat K, Schmitt A, Hasan MY: Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of ranitidine. J Appl Toxicol. 2005 Jan-Feb;25(1):60-7. [PubMed:15669026]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Petroianu GA, Arafat K, Schmitt A, Hasan MY: Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of ranitidine. J Appl Toxicol. 2005 Jan-Feb;25(1):60-7. [PubMed:15669026]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Details
4. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Bednarczyk D, Ekins S, Wikel JH, Wright SH: Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98. [PubMed:12606755]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE: Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res. 2000 Dec;17(12):1456-60. [PubMed:11303953]
  2. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
  3. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019]
  4. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Tahara H, Kusuhara H, Chida M, Fuse E, Sugiyama Y: Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther. 2006 Mar;316(3):1187-94. Epub 2005 Nov 16. [PubMed:16291876]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34